Score one win for Ontario province in the field of economic development. Sanofi Pasteur, the vaccine arm of Sanofi-Aventis, will build a C$100 million R&D facility in Toronto with the province chipping in C$13.9 million through its Biopharmaceutical Investment Program.
Researchers will target pediatric combination vaccines, pneumococcal protein vaccines and cancer vaccines. Look for the grand opening in 2010.
- check out the AFX report [1]
Related Articles:
Sanofi licenses technology for new TB vaccine. Sanofi report [2]
Maxygen, Sanofi Pasteur ink $24.5M vaccine deal. Sanofi report [3]
Canada's streamlined approval process raises protests. Canada report [4]
Canada's drug market slowing. Market report [5]
Links:
[1] http://money.cnn.com/news/newsfeeds/articles/newstex/AFX-0013-24515327.htm
[2] http://www.fiercebioresearcher.com/vaccines/story/sanofi-licenses-technology-for-new-tb-vaccine/2008-02-14
[3] http://www.fiercebiotech.com/story/maxygen-sanofi-pasteur-ink-24-5m-vaccine-deal/2007-12-04
[4] http://www.fiercebiotech.com/story/canada-s-streamlined-approval-process-raises-protests/2008-04-09
[5] http://www.fiercepharma.com/story/also-noted-canadas-drug-market-slowing-gsk-files-promacta-approval/2007-12-20